静脉化疗和植物性膳食补充剂 (CIVCAP)
单中心、前瞻性、非干预性研究,对在日间医院接受化疗的辅助性乳腺癌患者服用膳食补充剂进行定量和定性分析
More and more patients report taking dietary supplements based on herbal medicine, aromatherapy, vitamintherapy,... in the course of their detoxifying anticancer chemotherapy, to stimulate the immune defenses, to relieve and/or decrease the side effects of chemo or even to act against cancer. At European level, there are between 15 and 73% of patients treated for cancer taking a dietary supplement (in particular phytotherapy) or a great heterogeneity according to the studies. However, there is still little evidence of the efficacy of these dietary supplements. A large proportion of patients do not seem to inform their doctor about the use of dietary supplements. Patients using dietary supplements most often ignore the mode of action of these products and generally say they are not informed.
In 2015, at the West Cancerology Institute (ICO), 5 patient files were analyzed taking this type of treatment in addition to chemotherapy; in 2016, 24 files; 2017, 61 patient records and this continues to progress.
At the same time, a product appears very frequently associated with cancer chemotherapy: Desmodium Adscendens, an African plant with in vitro properties of liver protector. The Desmodium contains triterpene saponins, alkaloids, flavonoids, polyphenols, and tryptamine derivatives.
Morevover, several situations of patients undergoing chemotherapy and taking long-term Desmodium, with hepatic cytolyses were experienced, not explained by the usual treatments (case described in the literature).
Therefore, this study will evaluate these new therapeutic modalities that are included in the intake of chemotherapy in order to better know them to improve the therapeutic taking of patients and to focus on the impact of Desmodium in association with chemotherapy.
研究概览
详细说明
- Determine the quantitative impact of the use of dietary supplements by patients with breast cancer and treated in a neo-adjuvant and/or adjuvant condition by IV chemotherapy in day hospital.
- Determine an over-risk of disruption of liver balance in the population of patients taking Desmodium.
- Gather a critical mass of relevant information with the objective of carrying out the evaluation and analysis of cancer care practices related to the intake of dietary supplements.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Saint-Herblain、法国、44805
- Institut de Cancerologie de L'Ouest
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
Patients of the ICO René Gauducheau taken care at day hospital for IV chemotherapy treatment of breast cancer in neoadjuvant and/or adjuvant situation.
描述
Inclusion Criteria:
- breast cancer treated by intra-venous chemotherapy
- inclusion at the last cycle (cure)
- all chemotherapy cycles realised at ICO
Exclusion Criteria:
- no breast cancer
- metastatic breast cancer
- not all chemotherapy cycles realised at ICO
- patient who has not finished his chemotherapy
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:PROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
dietary supplements group with Desmodium
patients taking dietary supplements with Desmodium |
Patient questionaire to be completed by the patient at the last cycle Liver blood test to be performed from the first to the last chemotherapy cycle |
|
dietary supplements group without Desmodium
patients taking dietary supplements without Desmodium |
Patient questionaire to be completed by the patient at the last cycle Liver blood test to be performed from the first to the last chemotherapy cycle |
|
Control group
patients not taking any dietary supplements |
Liver blood test to be performed from the first to the last chemotherapy cycle |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Prevalence of Dietary Supplement Use During IV Chemotherapy
大体时间:12 months
|
Number of participants using dietary supplements during IV chemotherapy, including dietary supplements containing Desmodium and dietary supplements not containing Desmodium, compared with participants not using dietary supplements (control group). |
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of Hepatic Cytolysis From the First to the Last Treatment Cycle
大体时间:12 months
|
% of participants with hepatic cytolysis undergoing chemotherapy between the first and last treatments |
12 months
|
|
Percentage of Participants Taking Each Type of Dietary Supplement
大体时间:12 months
|
Dietary supplement use was extracted from patient-reported products recorded at the last chemotherapy cycle. Participants were classified into 'with Desmodium' and 'without Desmodium' groups based on the presence of Desmodium-containing products. Supplement categories (homeopathy, phytotherapy, aromatherapy, vitamin supplementation, mineral supplementation, probiotics, and gemmotherapy) were not mutually exclusive. Participants could report the use of more than one type of dietary supplement; therefore, percentages may total more than 100% within a group. |
12 months
|
合作者和调查者
调查人员
- 首席研究员:Emmanuelle BOURBOULOUX, MD、ICO
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.